Thirteen institutional investors co-led a $115 million upfront PIPE into a company — Quince Therapeutics — whose market cap sat in the low double-digit millions just months ago. That gap between capital raised and company size is the real story here, not the asset itself.
The asset is LAM-001, an inhaled formulation of rapamycin acquired through a stock-for-stock merger with Orphai Therapeutics. Rapamycin is a decades-old mTOR inhibitor; what Orphai engineered is a pulmonary-delivery formulation designed to concentrate drug in the lung and limit systemic immunosuppression — the side-effect liability that has historically made systemic rapamycin unattractive for chronic respiratory indications. The PH-ILD opportunity is real: roughly 86,000 U.S. patients with a condition that currently has one approved therapy in Merck’s sotatercept-adjacent competitive space, and a disease mechanism — parallel vascular remodeling and fibrosis — that mTOR inhibition theoretically hits at two nodes simultaneously. Phase 2a data presented at ATS in May were compelling enough to pull in Cormorant, Perceptive, Foresite, and Logos in a single syndicate, which is not a collection of investors that moves on concept alone.
The strategic logic for Quince is essentially a reverse-pivot: the company had a moribund pipeline and a listing but no real program with institutional momentum. Orphai brought the science, the management team — Brigette Roberts moves from Orphai CEO to Chief Corporate Affairs Officer — and now the syndicate. The $115 million upfront plus up to $72 million in warrants is structured to carry the program through three readouts: BOS Phase 2 data in Q1 2027, PH-ILD Phase 2b data in Q1 2028, and sarcoidosis-associated PH data in Q4 2028. Three catalysts in 30 months off a single inhaled formulation in related-but-distinct rare pulmonary indications is an aggressive parallel development posture, and it only works if the BOS readout in early 2027 holds up — BOS is the smaller indication (~17,000 U.S. patients) but the nearest data point, and a miss there resets the entire narrative around LAM-001’s mechanism before the larger PH-ILD bet is adjudicated.
The single marker that determines whether this deal’s logic survives is the Q1 2027 BOS Phase 2 readout — specifically whether LAM-001 shows measurable stabilization or improvement in FEV1 decline, which is the functional endpoint that will tell the field whether inhaled mTOR inhibition is doing actual disease modification or just delivering systemic rapamycin by a different route.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
